Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., … Cho, H. J. (2021). A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer J, 11(9), 149. https://doi.org/10.1038/s41408-021-00545-w

Ramasamy, Karthik, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, et al. “A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.” Blood Cancer J 11, no. 9 (September 3, 2021): 149. https://doi.org/10.1038/s41408-021-00545-w.

Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M, et al. A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer J. 2021 Sep 3;11(9):149.

Ramasamy, Karthik, et al. “A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.” Blood Cancer J, vol. 11, no. 9, Sept. 2021, p. 149. Pubmed, doi:10.1038/s41408-021-00545-w.

Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M, Tuchman SA, Laubach J, Gasparetto C, Chanan-Khan A, Hertzberg M, deMario M, Nueesch E, Chesne E, Franjkovic I, Lechner K, Kornacker M, Cho HJ. A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer J. 2021 Sep 3;11(9):149.